Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
30 Octubre 2023 - 5:00AM
Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company
dedicated to breaking through barriers in gene therapy and
neurology, today announced it will report third quarter 2023
financial and operating results after market close on Monday,
November 6, 2023. Subsequently, the Company will host a conference
call and webcast at 4:30 p.m. ET to review its financial and
operating results.
To participate via telephone and join the call live, please
register in advance here. Upon registration, telephone participants
will receive a confirmation email detailing how to join the
conference call, including the dial-in number and a unique
passcode. A live webcast of the call will also be available on the
Investors section of the Voyager website at
ir.voyagertherapeutics.com, and a replay of the call will be
available at the same link approximately two hours after its
completion. The replay will be available for at least 30 days
following the conclusion of the call.
About Voyager TherapeuticsVoyager
Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to
breaking through barriers in gene therapy and neurology. The
potential of both disciplines has been constrained by delivery
challenges; Voyager is leveraging cutting-edge expertise in capsid
discovery and deep neuropharmacology capabilities to address these
constraints. Voyager’s TRACER™ AAV capsid discovery platform has
generated novel capsids with high target delivery and blood-brain
barrier penetration at low doses, potentially addressing the narrow
therapeutic window associated with conventional gene therapy
delivery vectors. This platform is fueling alliances with Pfizer
Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo
Therapeutics, Inc., as well as multiple programs in Voyager’s own
pipeline. Voyager’s pipeline includes wholly owned and
collaborative preclinical programs in Alzheimer’s disease,
amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other
diseases of the central nervous system, with a focus on validated
targets and biomarkers to enable a path to rapid potential
proof-of-biology. For more information, visit
www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is
a trademark, of Voyager Therapeutics, Inc.
ContactsInvestorsInvestors@vygr.com
MediaPeg
Rusconiprusconi@vergescientific.com
Voyager Therapeutics (NASDAQ:VYGR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Voyager Therapeutics (NASDAQ:VYGR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024